ProCE Banner Activity

3-Yr Follow-up of ASCEND Phase III Trial: Acalabrutinib vs Idelalisib/Rituximab or Bendamustine/Rituximab in R/R CLL

Slideset Download
Conference Coverage
In patients with relapsed/refractory CLL, prolonged PFS with acalabrutinib vs idelalisib/rituximab or bendamustine/rituximab was maintained after a median follow-up of 3 years.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation